Annual Net Income
-$110.56 M
+$71.47 M+39.26%
31 December 2023
Summary:
Heron Therapeutics annual net profit is currently -$110.56 million, with the most recent change of +$71.47 million (+39.26%) on 31 December 2023. During the last 3 years, it has risen by +$116.72 million (+51.36%). HRTX annual net income is now -1392.79% below its all-time high of $8.55 million, reached on 31 December 2000.HRTX Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
-$4.85 M
+$4.39 M+47.50%
30 September 2024
Summary:
Heron Therapeutics quarterly net profit is currently -$4.85 million, with the most recent change of +$4.39 million (+47.50%) on 30 September 2024. Over the past year, it has increased by +$20.16 million (+80.61%). HRTX quarterly net income is now -125.12% below its all-time high of $19.30 million, reached on 31 March 2006.HRTX Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
-$27.97 M
+$20.16 M+41.89%
30 September 2024
Summary:
Heron Therapeutics TTM net profit is currently -$27.97 million, with the most recent change of +$20.16 million (+41.89%) on 30 September 2024. Over the past year, it has increased by +$91.74 million (+76.64%). HRTX TTM net income is now -326.56% below its all-time high of $12.34 million, reached on 31 March 2006.HRTX TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HRTX Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +39.3% | +80.6% | +76.6% |
| 3 y3 years | +51.4% | +90.8% | +87.8% |
| 5 y5 years | +38.2% | +85.6% | +85.8% |
HRTX Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +51.4% | -53.4% | +92.4% | at high | +87.9% |
| 5 y | 5 years | at high | +51.4% | -53.4% | +92.4% | at high | +88.1% |
| alltime | all time | -1392.8% | +51.4% | -125.1% | +92.4% | -326.6% | +88.1% |
Heron Therapeutics Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$4.85 M(-47.5%) | -$27.97 M(-41.9%) |
| June 2024 | - | -$9.23 M(+192.2%) | -$48.13 M(-40.5%) |
| Mar 2024 | - | -$3.16 M(-70.5%) | -$80.95 M(-26.8%) |
| Dec 2023 | -$110.56 M(-39.3%) | -$10.72 M(-57.1%) | -$110.56 M(-7.6%) |
| Sept 2023 | - | -$25.01 M(-40.5%) | -$119.70 M(-12.4%) |
| June 2023 | - | -$42.06 M(+28.4%) | -$136.60 M(-9.5%) |
| Mar 2023 | - | -$32.77 M(+64.9%) | -$150.90 M(-17.1%) |
| Dec 2022 | -$182.02 M(-17.5%) | -$19.87 M(-52.6%) | -$182.02 M(-16.0%) |
| Sept 2022 | - | -$41.91 M(-25.6%) | -$216.80 M(-4.6%) |
| June 2022 | - | -$56.36 M(-11.8%) | -$227.30 M(-2.0%) |
| Mar 2022 | - | -$63.89 M(+16.9%) | -$231.96 M(+5.1%) |
| Dec 2021 | -$220.68 M(-2.9%) | -$54.65 M(+4.3%) | -$220.68 M(-3.3%) |
| Sept 2021 | - | -$52.41 M(-14.1%) | -$228.32 M(-2.5%) |
| June 2021 | - | -$61.02 M(+16.0%) | -$234.14 M(+2.6%) |
| Mar 2021 | - | -$52.61 M(-15.5%) | -$228.31 M(+0.5%) |
| Dec 2020 | -$227.28 M(+11.0%) | -$62.28 M(+7.0%) | -$227.28 M(+2.0%) |
| Sept 2020 | - | -$58.23 M(+5.5%) | -$222.92 M(+12.4%) |
| June 2020 | - | -$55.19 M(+7.0%) | -$198.28 M(+2.6%) |
| Mar 2020 | - | -$51.58 M(-10.9%) | -$193.32 M(-5.6%) |
| Dec 2019 | -$204.75 M(+14.5%) | -$57.92 M(+72.4%) | -$204.75 M(+4.3%) |
| Sept 2019 | - | -$33.59 M(-33.1%) | -$196.39 M(-2.4%) |
| June 2019 | - | -$50.22 M(-20.3%) | -$201.14 M(+6.1%) |
| Mar 2019 | - | -$63.01 M(+27.1%) | -$189.59 M(+6.0%) |
| Dec 2018 | -$178.84 M(-9.4%) | -$49.56 M(+29.2%) | -$178.84 M(-6.7%) |
| Sept 2018 | - | -$38.35 M(-0.8%) | -$191.77 M(-1.8%) |
| June 2018 | - | -$38.67 M(-26.0%) | -$195.29 M(-2.1%) |
| Mar 2018 | - | -$52.27 M(-16.4%) | -$199.42 M(+1.0%) |
| Dec 2017 | -$197.48 M(+14.1%) | -$62.49 M(+49.3%) | -$197.48 M(+7.9%) |
| Sept 2017 | - | -$41.87 M(-2.2%) | -$182.96 M(-3.5%) |
| June 2017 | - | -$42.80 M(-15.0%) | -$189.60 M(-0.2%) |
| Mar 2017 | - | -$50.33 M(+4.9%) | -$190.03 M(+9.8%) |
| Dec 2016 | -$173.14 M(+77.4%) | -$47.96 M(-1.1%) | -$173.14 M(+10.7%) |
| Sept 2016 | - | -$48.51 M(+12.2%) | -$156.42 M(+19.8%) |
| June 2016 | - | -$43.23 M(+29.2%) | -$130.59 M(+18.2%) |
| Mar 2016 | - | -$33.45 M(+7.1%) | -$110.47 M(+13.2%) |
| Dec 2015 | -$97.59 M(+27.8%) | -$31.24 M(+37.8%) | -$97.59 M(+12.2%) |
| Sept 2015 | - | -$22.67 M(-1.9%) | -$86.97 M(+4.2%) |
| June 2015 | - | -$23.11 M(+12.3%) | -$83.50 M(+5.2%) |
| Mar 2015 | - | -$20.57 M(-0.3%) | -$79.40 M(+4.0%) |
| Dec 2014 | -$76.37 M(+38.1%) | -$20.62 M(+7.5%) | -$76.37 M(+9.4%) |
| Sept 2014 | - | -$19.19 M(+1.0%) | -$69.79 M(+10.0%) |
| June 2014 | - | -$19.01 M(+8.4%) | -$63.47 M(+6.0%) |
| Mar 2014 | - | -$17.54 M(+24.9%) | -$59.87 M(+8.3%) |
| Dec 2013 | -$55.28 M(+136.8%) | -$14.04 M(+9.1%) | -$55.28 M(+12.9%) |
| Sept 2013 | - | -$12.87 M(-16.5%) | -$48.98 M(+16.0%) |
| June 2013 | - | -$15.41 M(+19.0%) | -$42.22 M(+34.6%) |
| Mar 2013 | - | -$12.95 M(+67.4%) | -$31.38 M(+34.4%) |
| Dec 2012 | -$23.35 M(+97.6%) | -$7.74 M(+26.4%) | -$23.35 M(+17.5%) |
| Sept 2012 | - | -$6.12 M(+34.0%) | -$19.87 M(+10.7%) |
| June 2012 | - | -$4.57 M(-7.2%) | -$17.95 M(+17.2%) |
| Mar 2012 | - | -$4.92 M(+15.5%) | -$15.32 M(+29.6%) |
| Dec 2011 | -$11.81 M(+60.8%) | -$4.26 M(+1.4%) | -$11.81 M(+29.1%) |
| Sept 2011 | - | -$4.20 M(+117.5%) | -$9.15 M(+38.2%) |
| June 2011 | - | -$1.93 M(+36.2%) | -$6.62 M(-20.0%) |
| Mar 2011 | - | -$1.42 M(-11.1%) | -$8.27 M(+12.6%) |
| Dec 2010 | -$7.35 M(-26.7%) | -$1.60 M(-4.5%) | -$7.35 M(-4.1%) |
| Sept 2010 | - | -$1.67 M(-53.3%) | -$7.66 M(+6.4%) |
| June 2010 | - | -$3.58 M(+623.8%) | -$7.21 M(-4.7%) |
| Mar 2010 | - | -$495.00 K(-74.1%) | -$7.56 M(-24.6%) |
| Dec 2009 | -$10.03 M(-56.6%) | -$1.91 M(+57.6%) | -$10.03 M(-16.9%) |
| Sept 2009 | - | -$1.21 M(-69.2%) | -$12.06 M(-29.3%) |
| June 2009 | - | -$3.94 M(+33.1%) | -$17.05 M(-11.4%) |
| Mar 2009 | - | -$2.96 M(-25.0%) | -$19.24 M(-16.8%) |
| Dec 2008 | -$23.13 M(+14.7%) | -$3.95 M(-36.4%) | -$23.13 M(-14.0%) |
| Sept 2008 | - | -$6.21 M(+1.2%) | -$26.88 M(+6.0%) |
| June 2008 | - | -$6.13 M(-10.4%) | -$25.36 M(+20.7%) |
| Mar 2008 | - | -$6.84 M(-11.1%) | -$21.01 M(+4.2%) |
| Dec 2007 | -$20.16 M(-482.9%) | -$7.70 M(+64.4%) | -$20.16 M(+11.2%) |
| Sept 2007 | - | -$4.68 M(+163.8%) | -$18.13 M(+5.0%) |
| June 2007 | - | -$1.78 M(-70.4%) | -$17.26 M(-13.8%) |
| Mar 2007 | - | -$6.00 M(+5.9%) | -$20.03 M(-480.4%) |
| Dec 2006 | $5.27 M(-164.1%) | -$5.67 M(+48.4%) | $5.27 M(-36.8%) |
| Sept 2006 | - | -$3.82 M(-16.1%) | $8.33 M(-19.9%) |
| June 2006 | - | -$4.55 M(-123.6%) | $10.40 M(-15.7%) |
| Mar 2006 | - | $19.30 M(-841.4%) | $12.34 M(-250.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2005 | -$8.21 M(-11.0%) | -$2.60 M(+49.3%) | -$8.21 M(+4.4%) |
| Sept 2005 | - | -$1.74 M(-33.1%) | -$7.87 M(-2.2%) |
| June 2005 | - | -$2.61 M(+107.6%) | -$8.04 M(+2.1%) |
| Mar 2005 | - | -$1.26 M(-44.4%) | -$7.88 M(-14.6%) |
| Dec 2004 | -$9.22 M(+111.3%) | -$2.26 M(+17.5%) | -$9.22 M(+10.5%) |
| Sept 2004 | - | -$1.92 M(-21.4%) | -$8.34 M(+11.5%) |
| June 2004 | - | -$2.44 M(-6.0%) | -$7.48 M(+6.9%) |
| Mar 2004 | - | -$2.60 M(+88.6%) | -$7.00 M(+60.4%) |
| Dec 2003 | -$4.36 M(+15.5%) | -$1.38 M(+30.2%) | -$4.36 M(+35.8%) |
| Sept 2003 | - | -$1.06 M(-46.0%) | -$3.21 M(+0.2%) |
| June 2003 | - | -$1.96 M(-5864.7%) | -$3.21 M(+17.1%) |
| Mar 2003 | - | $34.00 K(-115.0%) | -$2.74 M(-27.5%) |
| Dec 2002 | -$3.78 M(+50.3%) | -$227.00 K(-78.4%) | -$3.78 M(-27.9%) |
| Sept 2002 | - | -$1.05 M(-29.5%) | -$5.24 M(+94.4%) |
| June 2002 | - | -$1.49 M(+48.4%) | -$2.69 M(+12.3%) |
| Mar 2002 | - | -$1.01 M(-40.4%) | -$2.40 M(-4.6%) |
| Dec 2001 | -$2.51 M(-129.4%) | -$1.69 M(-213.1%) | -$2.51 M(+3.9%) |
| Sept 2001 | - | $1.49 M(-224.5%) | -$2.42 M(-136.4%) |
| June 2001 | - | -$1.20 M(+6.8%) | $6.65 M(-7.8%) |
| Mar 2001 | - | -$1.12 M(-29.6%) | $7.21 M(-15.7%) |
| Dec 2000 | $8.55 M(-507.2%) | -$1.59 M(-115.1%) | $8.55 M(+33.8%) |
| Sept 2000 | - | $10.56 M(-1766.1%) | $6.39 M(-279.7%) |
| June 2000 | - | -$633.70 K(-387.7%) | -$3.56 M(+35.6%) |
| Mar 2000 | - | $220.30 K(-105.9%) | -$2.62 M(+3.1%) |
| Dec 1999 | -$2.10 M(-22.2%) | -$3.75 M(-715.1%) | -$2.54 M(+42.1%) |
| Sept 1999 | - | $610.10 K(+103.4%) | -$1.79 M(-5.8%) |
| June 1999 | - | $300.00 K(0.0%) | -$1.90 M(-5.0%) |
| Mar 1999 | - | $300.00 K(-110.0%) | -$2.00 M(-13.0%) |
| Dec 1998 | -$2.70 M(+50.0%) | -$3.00 M(-700.0%) | -$2.30 M(+360.0%) |
| Sept 1998 | - | $500.00 K(+150.0%) | -$500.00 K(-64.3%) |
| June 1998 | - | $200.00 K(-116.7%) | -$1.40 M(-22.2%) |
| Dec 1997 | -$1.80 M(-80.9%) | -$1.20 M(+200.0%) | -$1.80 M(-52.6%) |
| Sept 1997 | - | -$400.00 K(-33.3%) | -$3.80 M(-30.9%) |
| June 1997 | - | -$600.00 K(-250.0%) | -$5.50 M(-21.4%) |
| Mar 1997 | - | $400.00 K(-112.5%) | -$7.00 M(-25.5%) |
| Dec 1996 | -$9.40 M(0.0%) | -$3.20 M(+52.4%) | -$9.40 M(-12.1%) |
| Sept 1996 | - | -$2.10 M(0.0%) | -$10.70 M(+0.9%) |
| June 1996 | - | -$2.10 M(+5.0%) | -$10.60 M(+1.0%) |
| Mar 1996 | - | -$2.00 M(-55.6%) | -$10.50 M(+11.7%) |
| Dec 1995 | -$9.40 M(-4.1%) | -$4.50 M(+125.0%) | -$9.40 M(+27.0%) |
| Sept 1995 | - | -$2.00 M(0.0%) | -$7.40 M(-8.6%) |
| June 1995 | - | -$2.00 M(+122.2%) | -$8.10 M(-8.0%) |
| Mar 1995 | - | -$900.00 K(-64.0%) | -$8.80 M(-9.3%) |
| Dec 1994 | -$9.80 M(-1.0%) | -$2.50 M(-7.4%) | -$9.70 M(-5.8%) |
| Sept 1994 | - | -$2.70 M(0.0%) | -$10.30 M(+2.0%) |
| June 1994 | - | -$2.70 M(+50.0%) | -$10.10 M(-1.0%) |
| Mar 1994 | - | -$1.80 M(-41.9%) | -$10.20 M(0.0%) |
| Dec 1993 | -$9.90 M(+76.8%) | -$3.10 M(+24.0%) | -$10.20 M(+14.6%) |
| Sept 1993 | - | -$2.50 M(-10.7%) | -$8.90 M(+21.9%) |
| June 1993 | - | -$2.80 M(+55.6%) | -$7.30 M(+32.7%) |
| Mar 1993 | - | -$1.80 M(0.0%) | -$5.50 M(-1.8%) |
| Dec 1992 | -$5.60 M(+30.2%) | -$1.80 M(+100.0%) | -$5.60 M(+5.7%) |
| Sept 1992 | - | -$900.00 K(-10.0%) | -$5.30 M(-5.4%) |
| June 1992 | - | -$1.00 M(-47.4%) | -$5.60 M(+9.8%) |
| Mar 1992 | - | -$1.90 M(+26.7%) | -$5.10 M(+18.6%) |
| Dec 1991 | -$4.30 M(+10.3%) | -$1.50 M(+25.0%) | -$4.30 M(+26.5%) |
| Sept 1991 | - | -$1.20 M(+140.0%) | -$3.40 M(0.0%) |
| June 1991 | - | -$500.00 K(-54.5%) | -$3.40 M(-15.0%) |
| Mar 1991 | - | -$1.10 M(+83.3%) | -$4.00 M(+5.3%) |
| Dec 1990 | -$3.90 M(-13.3%) | -$600.00 K(-50.0%) | -$3.80 M(-11.6%) |
| Sept 1990 | - | -$1.20 M(+9.1%) | -$4.30 M(+7.5%) |
| June 1990 | - | -$1.10 M(+22.2%) | -$4.00 M(+5.3%) |
| Mar 1990 | - | -$900.00 K(-18.2%) | -$3.80 M(-13.6%) |
| Dec 1989 | -$4.50 M(-10.0%) | -$1.10 M(+22.2%) | -$4.40 M(-15.4%) |
| Sept 1989 | - | -$900.00 K(0.0%) | -$5.20 M(-10.3%) |
| June 1989 | - | -$900.00 K(-40.0%) | -$5.80 M(-3.3%) |
| Mar 1989 | - | -$1.50 M(-21.1%) | -$6.00 M(+20.0%) |
| Dec 1988 | -$5.00 M(+31.6%) | -$1.90 M(+26.7%) | -$5.00 M(+28.2%) |
| Sept 1988 | - | -$1.50 M(+36.4%) | -$3.90 M(+8.3%) |
| June 1988 | - | -$1.10 M(+120.0%) | -$3.60 M(+5.9%) |
| Mar 1988 | - | -$500.00 K(-37.5%) | -$3.40 M(-10.5%) |
| Dec 1987 | -$3.80 M | -$800.00 K(-33.3%) | -$3.80 M(+26.7%) |
| Sept 1987 | - | -$1.20 M(+33.3%) | -$3.00 M(+66.7%) |
| June 1987 | - | -$900.00 K(0.0%) | -$1.80 M(+100.0%) |
| Mar 1987 | - | -$900.00 K | -$900.00 K |
FAQ
- What is Heron Therapeutics annual net profit?
- What is the all time high annual net income for Heron Therapeutics?
- What is Heron Therapeutics annual net income year-on-year change?
- What is Heron Therapeutics quarterly net profit?
- What is the all time high quarterly net income for Heron Therapeutics?
- What is Heron Therapeutics quarterly net income year-on-year change?
- What is Heron Therapeutics TTM net profit?
- What is the all time high TTM net income for Heron Therapeutics?
- What is Heron Therapeutics TTM net income year-on-year change?
What is Heron Therapeutics annual net profit?
The current annual net income of HRTX is -$110.56 M
What is the all time high annual net income for Heron Therapeutics?
Heron Therapeutics all-time high annual net profit is $8.55 M
What is Heron Therapeutics annual net income year-on-year change?
Over the past year, HRTX annual net profit has changed by +$71.47 M (+39.26%)
What is Heron Therapeutics quarterly net profit?
The current quarterly net income of HRTX is -$4.85 M
What is the all time high quarterly net income for Heron Therapeutics?
Heron Therapeutics all-time high quarterly net profit is $19.30 M
What is Heron Therapeutics quarterly net income year-on-year change?
Over the past year, HRTX quarterly net profit has changed by +$20.16 M (+80.61%)
What is Heron Therapeutics TTM net profit?
The current TTM net income of HRTX is -$27.97 M
What is the all time high TTM net income for Heron Therapeutics?
Heron Therapeutics all-time high TTM net profit is $12.34 M
What is Heron Therapeutics TTM net income year-on-year change?
Over the past year, HRTX TTM net profit has changed by +$91.74 M (+76.64%)